Clinical Trial Update: Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) [Phase 2]

View source ↗

Summary

Phase II clinical trial of pacritinib for Kaposi sarcoma herpesvirus–associated multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma-associated Herpesvirus Associated Multicentric Castleman Disease
• Kshv Inflammatory Cytokine Syndrome

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease | Phase 2 | Status: RECRUITING